3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Ovarian Neoplasms
7
Fallopian Tube Neoplasms
6
Breast Neoplasms
6
Neoplasms
4
Sarcoma
3
Triple Negative Breast Neoplasms
2
Neoplasm Metastasis
2
Multi-centric Castleman's Disease
2
Lymphoma, B-Cell
2
Sarcoma, Kaposi
1
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Macular dystrophy, corneal type 1
1
Lymphoproliferative Disorders
1
Lymphoma, Primary Effusion
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, AIDS-Related
1
Lymphoma
1
Lymphadenopathy
1
Lung Neoplasms
1
Leukemia-Lymphoma, Adult T-Cell
1
Kidney Neoplasms
1
Invasive Breast Cancer
1
Hereditary Sensory and Autonomic Neuropathies
1
HIV Infections
1
Glioma
1
Fallopian Tube Mucinous Adenocarcinoma
1
Interventions
pembrolizumab
33
Cisplatin
11
Paclitaxel
9
lenvatinib
6
Carboplatin
6
belzutifan
5
Saline Solution
4
Pemetrexed
4
Oxaliplatin
4
Fluorouracil
4
Leucovorin
3
Etoposide
3
Docetaxel
3
Albumin-Bound Paclitaxel
3
130-nm albumin-bound paclitaxel
3
olaparib
2
enfortumab vedotin
2
durvalumab
2
Radiotherapy
2
Levoleucovorin
2
Glucose
2
Capecitabine
2
Bevacizumab
2
zanidatamab
1
tislelizumab
1
sacituzumab govitecan
1
liposomal doxorubicin
1
enzalutamide
1
balstilimab
1
avelumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
liposomal doxorubicin
×
Clear all
NCT04895358
2026-03-11
KEYNOTE-B49
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
340 enrolled